Savara to report second quarter 2019 financial results and provide business update

Austin, texas--(business wire)--savara inc. (nasdaq: svra), an orphan lung disease company, today announced that the company will report second quarter 2019 financial results and provide a business update on thursday, august 8, 2019. savara management will host a conference call at 4:30 p.m. eastern time (et)/1:30 p.m. pacific time (pt). shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the u.s., (855) 669-9657 from canada, and (412) 542-4127 from elsewhere outside the u.s. and request the “savara inc.” call. a live webcast of the conference call will be available online in the investors section of savara’s website at https://www.savarapharma.com/investors/events-presentations/. approximately one hour after the call, a replay of the webcast will be available on savara’s website for 30 days, and a telephone replay will be available through august 15, 2019 by dialing (877) 344-7529 from the u.s., (855) 669-9658 from canada and (412) 317-0088 from elsewhere outside the u.s. and entering the replay access code 10133438. about savara savara is an orphan lung disease company. savara’s pipeline comprises molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (gm-csf) in phase 3 development for autoimmune pulmonary alveolar proteinosis (apap), in phase 2a development for nontuberculous mycobacterial (ntm) lung infection in both non-cystic fibrosis (cf) and cf-affected individuals with chronic ntm lung infection; and aerovanc, a phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant staphylococcus aureus (mrsa) lung infection in cf. savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. the most recent acquisition is aerosolized amikacin/fosfomycin, a phase 2-ready combination antibiotic for which the initial indication will focus on non-cf bronchiectasis patients with chronic lung infection and frequent exacerbations. savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. more information can be found at www.savarapharma.com. (twitter: @savarapharma, linkedin: www.linkedin.com/company/savara-pharmaceuticals/)
SVRA Ratings Summary
SVRA Quant Ranking